Clinical trials
Colitis clinical trials
Below are recruiting colitis clinical trials, each written for real people, not researchers. We’re tracking 308 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05666960RecruitingPhase 1
Study drug R-3750 for mild to moderate ulcerative colitis
This Phase 1 study tests whether R-3750 is safe in people with mild to moderate ulcerative colitis and looks for early signs it could help. You may be able to join if you have stable treatment, confirmed diagnosis, and meet several health and medication timing rules.
Valencia, CaliforniaAges 18–65 - NCT07845487RecruitingPhase 2
Study of PALI-2108 for moderate to severe ulcerative colitis
This trial tests an experimental drug called PALI-2108 against a placebo (a dummy treatment) for people with moderate to severe ulcerative colitis. It aims to see if PALI-2108 can help reduce symptoms and improve quality of life.
Sun City, ArizonaAges 18–75 - NCT07415044RecruitingPhase 2
Study of LY4268989 for moderate to severe ulcerative colitis
This study tests an investigational medication called LY4268989 for adults with moderate to severe ulcerative colitis (UC). It's for people who have tried other treatments without success. The goal is to see if the drug can reduce inflammation and improve symptoms.
Phoenix, ArizonaAges 18–80 - NCT06899789Recruiting
Long-term follow-up of colitis from checkpoint inhibitors
This study follows people who developed colitis (inflammation in the colon) after receiving immune checkpoint inhibitors for cancer. Researchers want to learn about long-term effects and outcomes.
Pavia, PaviaAges 18 years+ - NCT07012395RecruitingPhase 2
Long-acting antibodies for moderate to severe ulcerative colitis
This study tests new long-acting antibodies, given alone or in combination, for people with moderate to severe ulcerative colitis. The goal is to see if these treatments can help reduce inflammation and improve symptoms.
Canoga Park, CaliforniaAges 18–75 - NCT06420492RecruitingPhase 2
New treatments for severe ulcerative colitis flare
This trial tests new therapies for people with a severe UC flare that hasn't improved after 5 days of high-dose steroids. It aims to find more effective options to control symptoms and avoid hospitalization.
Chestnut Hill, MassachusettsAges 18–75 - NCT05628701Recruiting
Testing two UC surgery reconstructions after colectomy
This trial compares two ways of reconnecting the bowel after subtotal colectomy and ileostomy in people with ulcerative colitis (UC). It may help determine which surgical option works best when the rectum is calm enough to manage with topical mesalazine alone.
GothenburgAges 18–60 - NCT07652294Enrolling by invitationPhase 2
Long-term safety of antibodies for IBD maintenance
This trial is testing long-lasting antibodies given alone or in combinations to keep IBD under control over the long term. It's for people who already did well in the initial study and want to continue treatment.
Lancaster, CaliforniaAges 18 years+ - NCT07632573RecruitingPhase 1
Safety Study of BDHK-2009 Tablets in Healthy Adults
This is an early-stage safety study testing a new experimental tablet called BDHK-2009 in healthy volunteers with no major illnesses. Researchers want to make sure the drug is safe and well-tolerated before testing it in people with medical conditions.
Hangzhou, ZhejiangAges 18–55 - NCT07463183RecruitingPhase 2
Study of MK-8690 for moderate to severe ulcerative colitis
This trial tests an investigational drug called MK-8690 for people with moderate to severe ulcerative colitis (UC) who haven't responded well to other treatments or can't tolerate them. The study aims to see if the drug can help control UC symptoms safely.
Anaheim, CaliforniaAges 18–75 - NCT07333716RecruitingPhase 2
Desloratadine for mild to moderate UC
This trial tests whether desloratadine, an allergy medicine (antihistamine), can help reduce inflammation in people with mild to moderate ulcerative colitis. All participants must already be taking mesalamine and cannot be on other stronger UC treatments.
Shibīn al Kawm, MenofiaAges 18–65 - NCT06850727RecruitingPhase 2
Study of OD-07656 then vedolizumab for ulcerative colitis
This trial tests a new drug, OD-07656, followed by vedolizumab, in people with moderate to severe ulcerative colitis. It aims to see if this approach is safe and helps control symptoms when other treatments have not worked well.
BirtinyaAges 18–75 - NCT06655415Recruiting
Study for family members at risk of inflammatory bowel disease
This study follows people who have a parent, sibling, or child with Crohn's disease or ulcerative colitis to help understand why some family members develop the condition. If you are 14 or older and do not already have IBD, you may be able to join.
Boston, MassachusettsAges 14 years+ - NCT05726396RecruitingPhase 2
Microbiome therapy for steroid-resistant immune colitis
This Phase 2 pilot study tests a “restorative microbiota therapy” (RMT) to treat colitis caused by immune checkpoint inhibitors when standard treatments like steroids are not working. It aims to see if this approach is safe and practical, and may improve diarrhea and gut inflammation.
Brainerd, MinnesotaAges 18 years+ - NCT04844606RecruitingPhase 3
Mirikizumab for kids with ulcerative colitis or Crohn’s
This study checks whether continuing mirikizumab (a medicine that calms gut inflammation) helps children with ulcerative colitis or Crohn’s disease after prior study treatment. It aims to see if staying on the medicine is beneficial and safe over time.
San Francisco, CaliforniaAges 2–19 - NCT07095634Recruiting
Heart risk study for Crohn's and colitis patients
This study looks at heart health in people with Crohn's disease or ulcerative colitis. It aims to understand the risk of heart problems over 2 years.
San Donato Milanese, MilanAges 16 years+ - NCT00001184Recruiting
Studying the immune system in Crohn's and colitis
This study collects blood and tissue samples to better understand how the immune system behaves in people with inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis. It aims to advance research rather than test a specific new treatment, and it also enrolls healthy volunteers for comparison.
Bethesda, MarylandAges 1 day–75 years - NCT07185009RecruitingPhase 3
Testing duvakitug for long-term ulcerative colitis control
This study tests the long-term safety and effectiveness of an experimental drug called duvakitug in people with moderate to severe ulcerative colitis. It is for those who have already responded well to treatment in a previous study and need ongoing care.
Tucson, ArizonaAges 16–80 - NCT07697456RecruitingPhase 2
Study of advanced therapies for Crohn's or ulcerative colitis
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
Dothan, AlabamaAges 18–75 - NCT07071519RecruitingPhase 3
Risankizumab for young people with ulcerative colitis
This study tests risankizumab (a medication that targets inflammation) in young people with ulcerative colitis who haven't improved enough on other treatments. It aims to see if risankizumab can help control symptoms and reduce bowel inflammation.
Phoenix, ArizonaAges 2–17 - NCT03804931RecruitingPhase 2/Phase 3
Stool transplant for moderate to severe ulcerative colitis
This trial tests whether transplanting stool bacteria into the colon (fecal microbiota transplantation) can improve ulcerative colitis symptoms in people with active, moderate to severe disease. If you qualify, the study team will also check that it’s safe for you and that you can safely undergo a scope exam.
Guangzhou, GuangdongAges 18–65 - NCT04043897RecruitingPhase 2
Oral rifaximin for active microscopic colitis flare
This trial tests whether an oral antibiotic called rifaximin can improve symptoms during a microscopic colitis flare. It aims to see if it is safe and effective for people whose colitis was confirmed by colon biopsy.
Evanston, IllinoisAges 18 years+ - NCT02421705Recruiting
Brain-gut sensitivity study in IBS and inflammatory bowel disease
This study checks how sensitive your gut is to normal stimuli in people with IBS, ulcerative colitis, Crohn’s disease, and in healthy volunteers. Results may help researchers understand why some people feel more abdominal discomfort and how that connects to inflammatory bowel conditions.
Leuven, Vlaams-BrabantAges 18–65 - NCT04721873RecruitingPhase 2
Weight-loss medicine for people with ulcerative colitis
This study tests whether a weight-loss medication, along with usual ulcerative colitis care, can help people who have both ulcerative colitis and obesity. It focuses on people with active symptoms or who need ongoing steroid medicine, and it also checks safety with heart, blood, infection, and mental-health screenings.
La Jolla, CaliforniaAges 18–80
Hear when a new Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Colitis trials by city
Studies with a site in or near these metro areas.
Colitis trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for colitis?
- Yes. Clin2 currently lists 308 recruiting colitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a colitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a colitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.